XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that Covid-ID Lab sits between a rapid antigen test and a centralized automated high-throughput PCR and offers diagnostic quality, fast results and ease of administration at point of care.
To view the full press release, visit https://ibn.fm/Pu8h3
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.